Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial

Adams, R, Brown, E, Brown, L et al. (14 more authors) (2018) Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial. Lancet Gastroenterology and Hepatology, 3 (3). pp. 162-171. ISSN 2468-1253

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the terms of the Creative Commons Attribution License (CC-BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Dates:
  • Accepted: 9 November 2017
  • Published (online): 15 December 2017
  • Published: March 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Pathology & Tumour Biology (Leeds)
Funding Information:
FunderGrant number
Cancer Research UKC588/A4994
Cancer Research UKCRUK 04 05 BUDGET
Cancer Research UKC588/A4994
Cancer Research UKCRUK 05 06 BUDGET
Department of HealthNCRN CC
MRC2012-005111-12
Depositing User: Symplectic Publications
Date Deposited: 02 Jan 2018 15:17
Last Modified: 29 Apr 2018 18:28
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/S2468-1253(17)30394-1

Share / Export

Statistics